You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

ID: GL 6-A-2018-1 mar 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review

Guideline Objective

This clinical practice guideline was produced jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). This guideline provides evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. The joint guideline is published in the Journal of Clinical Oncology (JCO) and can be accessed directly from the link "Full Report" below.

Patient Population

Patients with multiple myeloma

Intended Guideline Users

Medical oncologists, radiation oncologists, hematologists, surgeons, nurses, advanced practice providers, oncology pharmacists, and patients

Research Questions

  1. What criteria are used to assess eligibility for autologous stem cell transplant?

  2. What are the options for initial therapy before transplant? 

  3. What post-transplant therapy should be recommended?

  4. What are the response goals for the transplant eligible patient? 

  5. What are the options for initial therapy in transplant ineligible patients?

  6. What are the response goals following initial therapy for transplant ineligible patients? 

  7. What factors influence choice of first relapse therapy? 

  8. How does risk status influence therapy in myeloma (newly diagnosed and relapse)? 

  9. When and how should response assessment be performed?